Intermediate beta-thalassemia. Beta thalassemia
Conditions
Interventions
Intervention 1: Intervention group: Curcumin
Each dose contains 450 mg of turmeric rhizome powder and 50 mg of turmeric extract, which is standardized based on 5.47 mg of curcumin. three months
Three doses per day orally
Dineh Pharmaceutical Company, Iran. Intervention 2: Control group: Placebo
Each dose contains 500 mg of starch or flour. three months
Three doses per orally
Dineh Iran Pharmaceutical Company.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: gender male Lack of sensitivity to turmeric compounds The beta-thalassemia intermedia is approved by the doctor.
Exclusion criteria
Exclusion criteria: Cardiovascular disease Diabetes Gallbladder removal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum iron. Timepoint: At the beginning of the study (before the intervention) and three months after the start of curcumin intake. Method of measurement: Atomic absorption spectrometry? ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum ferritin concentrations. Timepoint: At the beginning of the study (before the intervention) and three months after the start of curcumin intake. Method of measurement: ELISA.;C-reactive protein (CRP). Timepoint: At the beginning of the study (before the intervention) and three months after the start of curcumin intake. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholamhossein Tamaddon
Shiraz University of Medical Sciences
Outcome results
None listed